Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.49 |
| ▸ | CCR5 | P51681 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.48 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6497698 | 0.87 | LMNA (0.53) | LRRK2CCR5USP2LMNAALDH1A1 | |
| SCHEMBL2167339 | 0.86 | LRRK2 (0.47) | LRRK2CCR5USP2LMNAALDH1A1 | |
| SCHEMBL2167940 | 0.86 | LRRK2 (0.47) | LRRK2CCR5USP2LMNAALDH1A1 | |
| SCHEMBL27563218 | 0.86 | LRRK2 (0.47) | LRRK2CCR5USP2LMNAALDH1A1 | |
| SCHEMBL8166488 | 0.83 | CCR5 (0.58) | LRRK2CCR5USP2LMNAALDH1A1 | |
| SCHEMBL17700696 | 0.83 | CCR5 (0.52) | LRRK2CCR5USP2LMNAALDH1A1 | |
| SCHEMBL3099590 | 0.82 | FABP4 (0.57) | LMNAALDH1A1PTGER1KDM4EL3MBTL1 | |
| SCHEMBL31065341 | 0.82 | CCR5 (0.50) | LRRK2CCR5USP2LMNAALDH1A1 | |
| SCHEMBL23599912 | 0.81 | USP28 (0.54) | LRRK2CCR5USP2LMNAALDH1A1 | |
| SCHEMBL6491785 | 0.81 | CCR5 (0.49) | LRRK2CCR5LMNAALDH1A1USP28 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187256-A1 | Benoxazinones/benzothiazinones as serine protease inhibitors | BERRYMAN KENT ALAN (US) | 2003-10-02 | — | — | US | disclosed |
| US-6509335-B1 | This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of | WARNER-LAMBERT COMPANY | 2003-01-21 | — | — | US | disclosed |
| EP-1068191-A1 | BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999050257-A1 | BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187256-A1 | Benoxazinones/benzothiazinones as serine protease inhibitors | HABP2, SPINT2, SERPINB1 | LRRK2 1773/4885CCR5 2520/4885USP2 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.